Form 8-K - Current report:
SEC Accession No. 0001437749-24-030297
Filing Date
2024-10-01
Accepted
2024-10-01 08:00:14
Documents
17
Period of Report
2024-10-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K aytu20240723_8k.htm   iXBRL 8-K 25755
2 EXHIBIT 99.1 ex_702328.htm EX-99.1 13807
7 logo01.jpg GRAPHIC 3651
8 logo.jpg GRAPHIC 4381
  Complete submission text file 0001437749-24-030297.txt   196072

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aytu-20241001.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aytu-20241001_def.xml EX-101.DEF 11807
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aytu-20241001_lab.xml EX-101.LAB 15858
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aytu-20241001_pre.xml EX-101.PRE 12022
19 EXTRACTED XBRL INSTANCE DOCUMENT aytu20240723_8k_htm.xml XML 2947
Mailing Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237
Business Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 241341356
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)